Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Goodwill (2023 - 2025)

Rein Therapeutics filings provide 3 years of Goodwill readings, the most recent being $6.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill changed 0.0% year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $6.3 million, changed 0.0% over the prior year.
  • Goodwill hit $6.3 million in Q4 2025 for Rein Therapeutics, roughly flat from $6.3 million in the prior quarter.
  • The five-year high for Goodwill was $6.3 million in Q4 2023, with the low at $6.3 million in Q4 2023.
  • Median Goodwill over the past 3 years was $6.3 million (2023), compared with a mean of $6.3 million.
  • The largest YoY upside for Goodwill was 0.0% in 2024 against a maximum downside of 0.0% in 2024.
  • Year by year, Goodwill stood at $6.3 million in 2023, then changed by 0.0% to $6.3 million in 2024, then changed by 0.0% to $6.3 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $6.3 million, $6.3 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.